NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome
Single-Group, Open-Label, Phase 2 Trial Results
NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome | Neurology Genetics
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Neuren Pharmaceuticals Limited. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Neuren Pharmaceuticals Limited a question about this update.